Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01552408 · ClinicalTrials.gov registry record · Phase 1
Efficacy & Safety Trial of Intravitreal Injections Combined With PRP for CSME Secondary to Diabetes Mellitus (DAVE)
A Phase 1 study of Diabetic Macular Edema, sponsored by David M. Brown, M.D..
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
- 3
- Study locations
NCT01552408: Completed Phase 1 study of Diabetic Macular Edema, sponsored by David M. Brown, M.D..
NCT01552408 is a Phase 1 study of Diabetic Macular Edema that has completed, run by David M. Brown, M.D.. The registered enrollment target is 29 participants, below the 3,794-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (99% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01552408, a Phase 1 study of Diabetic Macular Edema, has completed, sponsored by David M. Brown, M.D..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study is a Phase I/II, multicenter, randomized, study of the efficacy and safety of ranibizumab injection monotherapy verses a duel therapy of 0.3mg ranibizumab combined with ultra wide, 200° field angiography guided pan retinal photocoagulation in patients with CSME-CI secondary to diabetes mellitus (Type 1 or 2).
Primary Outcome
Assess the number of ranibizumab injections in the ranibizumab and targeted panretinal photocoagulation (PRP) with ranibizumab cohorts through Month 36.
Conditions Studied
Interventions
- DRUG 0.3 mg ranibizumab
- PROCEDURE Targeted Pan Retinal Photocoagulation
Study Locations (3)
Texas
- Retina Consultants of Houston - Houston
- Retina Consultants of Houston - Katy
- Retina Consultants of Houston - The Woodlands
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2012-03 |
| Est. Completion | 2017-05-18 |
| Phase | Phase 1 |
What the finished NCT01552408 record still lists
NCT01552408 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 3,794-participant average among 63 other Diabetic Macular Edema trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Diabetic Macular Edema appearing as the primary indexed condition, and to 2 interventions - of which 0.3 mg ranibizumab is the first listed.
NCT01552408 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT01552408 about?
NCT01552408 is a clinical study titled "Efficacy & Safety Trial of Intravitreal Injections Combined With PRP for CSME Secondary to Diabetes Mellitus (DAVE)". This study is a Phase I/II, multicenter, randomized, study of the efficacy and safety of ranibizumab injection monotherapy verses a duel therapy of 0.3mg ranibizumab combined with ultra wide, 200° field angiography guided pan retinal photocoagulation in patients with CSME-CI secondary to diabetes me...
What is the current status of trial NCT01552408?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2012-03. Estimated completion is 2017-05-18.
What conditions does trial NCT01552408 study?
This clinical trial studies the following conditions: Diabetic Macular Edema.
What interventions are being tested in trial NCT01552408?
The interventions under investigation include: 0.3 mg ranibizumab (DRUG), Targeted Pan Retinal Photocoagulation (PROCEDURE).
Who is sponsoring clinical trial NCT01552408?
This trial is sponsored by David M. Brown, M.D., which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01552408 being conducted?
This trial has 3 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Macular Edema
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01552408's enrollment target sits among peer trials
29 47th of 63 higher than 17 of 63 other Diabetic Macular Edema trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetic Macular Edema trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of K9 in Subjects With Diabetic Macular Edema (DME)
RECRUITING · Phase 1
-
EC-104 Intravitreal Implant for the Treatment of Diabetic Macular Edema
RECRUITING · Phase 1
-
Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME)
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema
RECRUITING · Phase 1
-
Kamuvudine-9 (K9) in Diabetic Macular Edema
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia